HomeCompareEPZM vs MRK

EPZM vs MRK: Dividend Comparison 2026

EPZM yields 136.05% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPZM wins by $15.34M in total portfolio value
10 years
EPZM
EPZM
● Live price
136.05%
Share price
$1.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.39M
Annual income
$6,293,323.05
Full EPZM calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EPZM vs MRK

📍 EPZM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPZMMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPZM + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPZM pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM
Annual income on $10K today (after 15% tax)
$11,564.63/yr
After 10yr DRIP, annual income (after tax)
$5,349,324.59/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, EPZM beats the other by $5,340,996.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + MRK for your $10,000?

EPZM: 50%MRK: 50%
100% MRK50/50100% EPZM
Portfolio after 10yr
$7.72M
Annual income
$3,151,560.60/yr
Blended yield
40.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EPZM
Analyst Ratings
10
Buy
5
Hold
1
Sell
Consensus: Buy
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys
0
MRK buys
0
No recent congressional trades found for EPZM or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPZMMRK
Forward yield136.05%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$15.39M$56.8K
Annual income after 10y$6,293,323.05$9,798.13
Total dividends collected$14.14M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: EPZM vs MRK ($10,000, DRIP)

YearEPZM PortfolioEPZM Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$24,305$13,605.44$11,206$366.19+$13.1KEPZM
2$56,912$30,905.26$12,650$502.35+$44.3KEPZM
3$128,528$67,631.59$14,407$694.19+$114.1KEPZM
4$280,268$142,743.86$16,585$967.82+$263.7KEPZM
5$590,792$290,905.24$19,342$1,363.89+$571.5KEPZM
6$1,205,245$573,097.64$22,913$1,947.19+$1.18MEPZM
7$2,382,274$1,092,661.12$27,662$2,823.89+$2.35MEPZM
8$4,567,482$2,018,449.47$34,159$4,173.35+$4.53MEPZM
9$8,503,963$3,616,756.90$43,337$6,308.80+$8.46MEPZM
10$15,392,564$6,293,323.05$56,776$9,798.13+$15.34MEPZM

EPZM vs MRK: Complete Analysis 2026

EPZMStock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EPZM vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHDEPZM vs JEPIEPZM vs OEPZM vs KOEPZM vs MAINEPZM vs JNJEPZM vs ABBVEPZM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.